This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Nifuroxazide is an antibiotic indicated in the treatment of susceptible gastrointestinal infections.

Generic Name
Nifuroxazide
DrugBank Accession Number
DB13855
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 275.22
Monoisotopic: 275.054220402
Chemical Formula
C12H9N3O5
Synonyms
  • Nifuroxazide
External IDs
  • RC-27109

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AMEBICOL®Nifuroxazide (200 mg) + Metronidazole (300 mg)Capsule, coatedOralBIOQUIMICO PHARMAS.A.2017-05-22Not applicableColombia flag
DIARSET NX® M CAPSULASNifuroxazide (200 mg) + Metronidazole (600 mg)Capsule, coatedOralCOLOMPACK S.A.2014-01-10Not applicableColombia flag
KRODEX F COMPUESTO SUSPENSIÓNNifuroxazide (4 g) + Metronidazole benzoate (5 g)SuspensionOralCOASPHARMA S.A.S.2007-02-06Not applicableColombia flag
KRODEX F COMPUESTO® CAPSULASNifuroxazide (200 mg) + Metronidazole (600 mg)Capsule, coatedOralCOASPHARMA S.A.S.2007-02-06Not applicableColombia flag
MEBINOL COMPLEXNifuroxazide (200 mg) + Metronidazole (600 mg)Capsule, coatedOralCOASPHARMA S.A.S.2008-10-10Not applicableColombia flag
METARSAL N CAPSULASNifuroxazide (200 mg) + Metronidazole (600 mg)Capsule, coatedOralCOLOMPACK S.A.2006-11-10Not applicableColombia flag
METARSAL SUSPENSIONNifuroxazide (4 g) + Metronidazole (5 g)SuspensionOralARBOFARMA S.A.S (ANTES ARBOFARMA S.A) (PLANTA DE LIQUIDOS Y SEMISOLIDOS)2006-11-102013-04-01Colombia flag
METRO F 400 CÁPSULASNifuroxazide (200 mg) + Metronidazole (400 mg)Capsule, coatedOralLABORATORIOS LEGRANDS.A.2007-09-18Not applicableColombia flag
METRO F SUSPENSIONNifuroxazide (4 g) + Metronidazole benzoate (5 g)SuspensionOralCOLOMPACK S.A.2018-09-25Not applicableColombia flag
METRONIDAZOL/NIFUROXAZIDA 300 MG/100 MG.Nifuroxazide (100 mg) + Metronidazole (300 mg)Capsule, liquid filledOralTECNOQUIMICAS S.A. (PLANTA JAMUNDI)2017-03-21Not applicableColombia flag

Categories

ATC Codes
A07AX03 — Nifuroxazide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzoic acids and derivatives. These are organic compounds containing a carboxylic acid substituent attached to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acids and derivatives
Alternative Parents
Nitrofurans / Nitroaromatic compounds / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Carboxylic acids and derivatives / Organopnictogen compounds
show 5 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 2-nitrofuran / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Benzoic acid or derivatives / Benzoyl / C-nitro compound / Carboxylic acid derivative / Furan / Heteroaromatic compound
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
PM5LI0P38J
CAS number
965-52-6
InChI Key
YCWSUKQGVSGXJO-NTUHNPAUSA-N
InChI
InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+
IUPAC Name
4-hydroxy-N'-[(1E)-(5-nitrofuran-2-yl)methylidene]benzohydrazide
SMILES
OC1=CC=C(C=C1)C(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O

References

General References
  1. INVIMA: Acta 15 (21 and 22 July 2015) [Link]
ChemSpider
4495115
BindingDB
50396177
RxNav
31782
ChEBI
135136
ChEMBL
CHEMBL244888
ZINC
ZINC000000001808
Wikipedia
Nifuroxazide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionOral
SuspensionOral4.483 g
TabletOral
SuspensionOral4 g
TabletOral200 mg
CapsuleOral200 MG
Capsule, coatedOral200 mg
CapsuleOral100 mg
Tablet, coatedOral
SuspensionOral
Capsule, coatedOral
SuspensionOral5 g
Capsule, coatedOral600 mg
Capsule, liquid filledOral
Tablet, film coatedOral
SyrupOral
SuspensionOral4.4 g
SuspensionOral218 mg/5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP2.59ALOGPS
logP1.75Chemaxon
logS-3.4ALOGPS
pKa (Strongest Acidic)8.33Chemaxon
pKa (Strongest Basic)-1.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area117.97 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity68.18 m3·mol-1Chemaxon
Polarizability26 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23